K-beauty is known for its innovation and meticulous attention to

detail in aesthetic enhancement. Now Letybo® offers

coveted K-beauty in an internationally proven toxin.

 

Why Letybo®? It’s Trusted.

​

Bringing K-beauty to the US

K-beauty is Known for High-quality, Innovative Formulations and

Intentional Beauty Regimens

LetibotulinumtoxinA – the active ingredient
• The #1 toxin in South Korea, the epicenter of beauty and skincare,

for 8 years and counting

• Approved and used in 65+ countries
• 31 million+ successful treatments to date

It’s Proven to Improve the Look of Frown Lines.

• In 3 international clinical studies (N=1,271),t the majority of patients injected with Letybo® (n=954) had either mildly noticeable or no frown lines 4 weeks after treatment

• Results may appear within 24 hours, with the majority of patients seeing results by Day 3 (75%)

• Improvement in frown lines may last up to 16 weeks

 

 

 

 

INDICATION Letybo° (letibotulinumtoxinA-wlbg) is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance ot moderate to severe alabellar lines associated with corrugator and or procerus

muscle activity in adult patients.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS Letybo contraindications include known hypersensitivity to any botulinum toxin preparation or to any of the components in the Letybo

formulation and infection at the iniection site.

WARNINGS AND PRECAUTIONS Spread of toxin effects; swallowing and breathing difficulties can lead to death. Seek immediate medical attention if respiratory, speech or

swallowing difficulties occur. The potency Units of Letybo° are not interchangeable with other preparations of botulinum toxin products. Potential serious adverse reactions after Letybo injections for unapproved uses. If a hypersensitivity reaction occurs, discontinue Letybo' and immediately initiate appropriate therapy. Adverse reports have been received involving the cardiovascular system, some with fatal outcomes. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular

disorder may exacerbate clinical effects of treatment. Use with caution in patients with compromised respiratory function or dysphagia.

ADVERSE REACTIONS

The most common adverse reaction was headache (2%)

DRUG INTERACTIONS Co-administration of Letybo' and aminoglycosides, anticholinergic agents, or any other agents that interfere with neuromuscular

transmission may potentiate the effect of Letybo, co-administer only with caution and close observation.

USE IN SPECIFIC POPULATIONS

Letybo' is not recommended for use in children, pregnant or lactating women

Please see Letybo° full Prescribing Information, including Boxed Warning and Medication Guide at bit. ly/BUbRZtP